Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Response to Lai.

Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS.

Am J Gastroenterol. 2019 Jul;114(7):1177-1178. doi: 10.14309/ajg.0000000000000312. No abstract available.

PMID:
31205133
2.

Impact of patient and disease characteristics on the efficacy and safety of eluxadoline for IBS-D: a subgroup analysis of phase III trials.

Lacy BE, Harris LA, Chang L, Lucak S, Gutman C, Dove LS, Covington PS, Lembo A.

Therap Adv Gastroenterol. 2019 Apr 15;12:1756284819841290. doi: 10.1177/1756284819841290. eCollection 2019.

3.

Evaluation of Eluxadoline Effect on Cardiac Repolarization.

Bonifacio L, Hunt TL, McIntyre G, Dove LS, Covington PS.

Clin Pharmacol Drug Dev. 2018 Sep;7(7):727-736. doi: 10.1002/cpdd.453. Epub 2018 Apr 16.

4.

Radar plots: A novel modality for displaying disparate data on the efficacy of eluxadoline for the treatment of irritable bowel syndrome with diarrhea.

Brenner DM, Dove LS, Andrae DA, Covington PS, Gutman C, Chey WD.

Neurogastroenterol Motil. 2018 Mar 25:e13331. doi: 10.1111/nmo.13331. [Epub ahead of print]

PMID:
29575372
5.

Response to Croteau and Barkin.

Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS.

Am J Gastroenterol. 2017 Oct;112(10):1617. doi: 10.1038/ajg.2017.256. No abstract available.

PMID:
28978962
6.

Safety of Eluxadoline in Patients With IBS-D Without a Gallbladder.

Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS.

Am J Gastroenterol. 2017 Oct;112(10):1619-1620. doi: 10.1038/ajg.2017.257. No abstract available.

PMID:
28978951
7.

Effect of Hepatic Impairment on Eluxadoline Pharmacokinetics.

Marbury TC, Berg JK, Dove LS, Covington PS.

J Clin Pharmacol. 2017 Nov;57(11):1454-1459. doi: 10.1002/jcph.964. Epub 2017 Jul 18. No abstract available.

8.

Corrigendum: Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.

Lacy BE, Chey WD, Cash BD, Lembo AJ, Dove LS, Covington PS.

Am J Gastroenterol. 2017 Jul;112(7):1210. doi: 10.1038/ajg.2017.152. Epub 2017 May 30.

PMID:
28555632
9.

Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.

Lacy BE, Chey WD, Cash BD, Lembo AJ, Dove LS, Covington PS.

Am J Gastroenterol. 2017 Jun;112(6):924-932. doi: 10.1038/ajg.2017.72. Epub 2017 Apr 18. Erratum in: Am J Gastroenterol. 2017 Jul;112(7):1210.

10.

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies.

Chey WD, Dove LS, Andrae DA, Covington PS.

Aliment Pharmacol Ther. 2017 May;45(10):1319-1328. doi: 10.1111/apt.14031. Epub 2017 Mar 22.

11.

Eluxadoline Demonstrates a Lack of Abuse Potential in Phase 2 and 3 Studies of Patients With Irritable Bowel Syndrome With Diarrhea.

Fant RV, Henningfield JE, Cash BD, Dove LS, Covington PS.

Clin Gastroenterol Hepatol. 2017 Jul;15(7):1021-1029.e6. doi: 10.1016/j.cgh.2017.01.026. Epub 2017 Feb 3.

12.

Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.

Cash BD, Lacy BE, Schoenfeld PS, Dove LS, Covington PS.

Am J Gastroenterol. 2017 Feb;112(2):365-374. doi: 10.1038/ajg.2016.542. Epub 2016 Dec 6.

13.

Abuse Potential and Pharmacodynamic Characteristics of Oral and Intranasal Eluxadoline, a Mixed μ- and κ-Opioid Receptor Agonist and δ-Opioid Receptor Antagonist.

Levy-Cooperman N, McIntyre G, Bonifacio L, McDonnell M, Davenport JM, Covington PS, Dove LS, Sellers EM.

J Pharmacol Exp Ther. 2016 Dec;359(3):471-481. Epub 2016 Sep 19.

14.

Eluxadoline for Irritable Bowel Syndrome with Diarrhea.

Lembo AJ, Lacy BE, Zuckerman MJ, Schey R, Dove LS, Andrae DA, Davenport JM, McIntyre G, Lopez R, Turner L, Covington PS.

N Engl J Med. 2016 Jan 21;374(3):242-53. doi: 10.1056/NEJMoa1505180.

15.

Molecular characterization of eluxadoline as a potential ligand targeting mu-delta opioid receptor heteromers.

Fujita W, Gomes I, Dove LS, Prohaska D, McIntyre G, Devi LA.

Biochem Pharmacol. 2014 Dec 1;92(3):448-56. doi: 10.1016/j.bcp.2014.09.015. Epub 2014 Sep 28.

16.

Eluxadoline benefits patients with irritable bowel syndrome with diarrhea in a phase 2 study.

Dove LS, Lembo A, Randall CW, Fogel R, Andrae D, Davenport JM, McIntyre G, Almenoff JS, Covington PS.

Gastroenterology. 2013 Aug;145(2):329-38.e1. doi: 10.1053/j.gastro.2013.04.006. Epub 2013 Apr 9.

17.

Homeostatic compensation maintains Ca2+ signaling functions in Purkinje neurons in the leaner mutant mouse.

Murchison D, Dove LS, Abbott LC, Griffith WH.

Cerebellum. 2002 Apr;1(2):119-27. Review.

PMID:
12882361
18.

Altered calcium homeostasis in cerebellar Purkinje cells of leaner mutant mice.

Dove LS, Nahm SS, Murchison D, Abbott LC, Griffith WH.

J Neurophysiol. 2000 Jul;84(1):513-24.

19.

Supplemental Content

Support Center